Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity
Reuters
Sep 04
Vyome Holdings Announces Promising Interim Results from Phase 2 Study of VT-1953 for Malignant Fungating Wounds, Highlights $1B Market Opportunity
Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced interim results from its investigator-initiated Phase 2 Proof of Concept (PoC) study of VT-1953 topical gel, which is being tested in patients with malignant fungating wounds (MFW). The interim results were first presented at the annual meeting of the American Association for Cancer Research. The study showed that VT-1953 significantly reduced the primary endpoint of malignant fungating wound-associated malodor, with statistical significance (P<0.001). Additionally, patients reported significant improvements in secondary endpoints, including lesion pain and quality of life, both with statistical significance (P<0.001). Vyome Co-founder Dr. Shiladitya Sengupta will further discuss these preliminary results and the MFW market in a live video conference scheduled for Monday, September 8, 2025. Full study results are anticipated in October 2026, and Vyome plans to engage with the FDA in early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904730668) on September 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.